|
|
Prepublished online as a Blood First Edition Paper on August 1, 2002; DOI 10.1182/blood-2002-04-1244.

Submitted April 26, 2002
Accepted July 15, 2002
Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system
Nadine Mayotte, Denis-Claude Roy, Jing Yao, Evert Kroon, and Guy Sauvageau*
Laboratory of Molecular Genetics of Stem Cells, Clinical Research Institute of Montreal, Montreal, PQ, Canada; Department of Medecine, University of Montreal, Montreal, QC, Canada; Division of Hematology, Maisoneuve-Rosemont Hospital, Montreal, QC, Canada
Department of Medecine, University of Montreal, Montreal, PQ, Canada; Division of Hematology, Maisoneuve-Rosemont Hospital, Montreal, PQ, Canada
Laboratory of Molecular Genetics of Stem Cells, Clinical Research Institute of Montreal, Montreal, PQ, Canada; Division of Hematology, Maisoneuve-Rosemont Hospital, Montreal, QC, Canada
Laboratory of Molecular Genetics of Stem Cells, Clinical Research Institute of Montreal, Montreal, PQ, Canada
Laboratory of Molecular Genetics of Stem Cells, Clinical Research Institute of Montreal, Montreal, PQ, Canada; Department of Medecine, University of Montreal, Montreal, PQ, Canada; Division of Hematology, Maisoneuve-Rosemont Hospital, Montreal, PQ, Canada
* Corresponding author; email: sauvagg{at}ircm.qc.ca.
Chronic myelogenous leukemia (CML) is a clonal stem cell disease caused by the BCR-ABL oncoprotein and is characterized, in its early phase, by excessive accumulation of mature myeloid cells which eventually leads to acute leukemia. The genetic events involved in CML progression to acute leukemia remain largely unknown. Recent studies have detected the presence of the NUP98-HOXA9 fusion oncogene in acute leukemia derived from CML patients which suggests that these 2 oncoproteins may interact and influence CML disease progression. Using in vitro purging of BCR-ABL-transduced mouse bone marrow cells, we can now report that recipients of bone marrow cells engineered to co-express BCR-ABL with NUP98-HOXA9 develop acute leukemia within 7-10 days post-transplantation. However no disease is detected for over 2 months in mice transplanted with bone marrow cells expressing either BCR-ABL or NUP98-HOXA9. We also provide evidence of high levels of HOXA9 expressed in leukemic blasts from acute phase CML patients and that it interacts significantly on a genetic level with BCR-ABL in our in vivo CML model. Together, these studies support a causative, as opposed to a consequential, role for NUP98-HOXA9 (and possibly HOXA9) in CML disease progression.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Roche-Lestienne, L. Deluche, S. Corm, I. Tigaud, S. Joha, N. Philippe, S. Geffroy, J.-L. Lai, F.-E. Nicolini, C. Preudhomme, et al.
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance
Blood,
April 1, 2008;
111(7):
3735 - 3741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Neering, T. Bushnell, S. Sozer, J. Ashton, R. M. Rossi, P.-Y. Wang, D. R. Bell, D. Heinrich, A. Bottaro, and C. T. Jordan
Leukemia stem cells in a genetically defined murine model of blast-crisis CML
Blood,
October 1, 2007;
110(7):
2578 - 2585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Y. Chung, G. Morrone, J. J. Schuringa, M. Plasilova, J.-H. Shieh, Y. Zhang, P. Zhou, and M. A.S. Moore
Enforced Expression of NUP98-HOXA9 in Human CD34+ Cells Enhances Stem Cell Proliferation
Cancer Res.,
December 15, 2006;
66(24):
11781 - 11791.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Rizo, E. Vellenga, G. de Haan, and J. J. Schuringa
Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?
Hum. Mol. Genet.,
October 15, 2006;
15(suppl_2):
R210 - R219.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Palmqvist, B. Argiropoulos, N. Pineault, C. Abramovich, L. M. Sly, G. Krystal, A. Wan, and R. K. Humphries
The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia
Blood,
August 1, 2006;
108(3):
1030 - 1036.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mamo, J. Krosl, E. Kroon, J. Bijl, A. Thompson, N. Mayotte, S. Girard, R. Bisaillon, N. Beslu, M. Featherstone, et al.
Molecular dissection of Meis1 reveals 2 domains required for leukemia induction and a key role for Hoxa gene activation
Blood,
July 15, 2006;
108(2):
622 - 629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Iwasaki, T. Kuwata, Y. Yamazaki, N. A. Jenkins, N. G. Copeland, M. Osato, Y. Ito, E. Kroon, G. Sauvageau, and T. Nakamura
Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model
Blood,
January 15, 2005;
105(2):
784 - 793.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Calabretta and D. Perrotti
The biology of CML blast crisis
Blood,
June 1, 2004;
103(11):
4010 - 4022.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Jiang, M. Stuible, Y. Chalandon, A. Li, W. Y. Chan, W. Eisterer, G. Krystal, A. Eaves, and C. Eaves
Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia
Blood,
October 15, 2003;
102(8):
2976 - 2984.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|